Amarin Pharmaceuticals (AMRN) +15.5% premarket as U.S. patent examiners appear poised to approve a family of key patents that could protect its AMR101 prescription fish oil pill from generic competition through 2030. Jefferies is bullish on the prospects for approval, reiterating its Buy rating on the shares and raising its target price to $26 from $24.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 25, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs